Seek Labs Awarded $2M USDA Grant for CRISPR Avian Flu Therapeutic
Seek Labs Awarded $2 Million Federal Grant for a Novel CRISPR-Based, Mutation-Resistant Therapeutic to Combat Avian Flu in Partnership with Canadian Food Inspection Agency USDA gra
Seek Labs Publishes Editorial Review on the Future of CRISPR Antivirals in an Era of AI-Designed Viral Threats
Seek Labs Publishes Editorial Review on the Future of CRISPR Antivirals in an Era of AI-Designed Viral Threats December 8, 2025 Read the full open-access review in Viruses Seek Lab
Seek Labs Publishes First Peer-Reviewed Paper Demonstrating A CRISPR-Based Therapeutic Is Effective Against African Swine Fever
Seek Labs Publishes First Peer-Reviewed Paper Demonstrating A CRISPR-Based Therapeutic Is Effective Against African Swine Fever November 17, 2025 SALT LAKE CITY, UT (Business Wire)
Seek Labs Expands Global Disease Atlas with Mapping of Hemorrhagic Fever Viruses through BioSeeker™
Seek Labs Expands Global Disease Atlas with Mapping of Hemorrhagic Fever Viruses through BioSeeker™ October 21, 2025 Salt Lake City, UT (Business Wire)–Seek Labs, a biotech com
Seek Labs Advances Development of Pan-Orthopoxvirus Therapeutic with BioSeeker™ and PTAP™
Seek Labs Advances Development of Pan-Orthopoxvirus Therapeutic with BioSeeker™ and PTAP™ October 7, 2025 BioSeeker mapped more than 10,000 isolates and identified targetable r
Seek Labs Maps Foot-and-Mouth Disease with BioSeeker™
Seek Labs Maps Foot-and-Mouth Disease with BioSeeker™ to Advance Development of a Pan-Target, Programmable Therapeutic September 9, 2025 Salt Lake City, UT (Business Wire) –
Seek Labs Maps High-Burden Mosquito-Borne Infectious Diseases with BioSeeker™
Seek Labs Maps High-Burden Mosquito-Borne Infectious Diseases with BioSeeker™, Accelerating Therapeutic Discovery for Chikungunya, West Nile Virus, and Zika August 5, 2025 Salt L
Seek Labs Announces Inclusion of Veterinary Diseases in Global Disease Atlas
Seek Labs Announces Inclusion of Veterinary Diseases in Global Disease Atlas, Accelerating Development of Therapeutics to Bolster Global Protein Supply Chains July 22, 2025 SALT LA
BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV) July 8, 2025 Read the Medium Article from our CEO, Jared Bauer